Results 81 to 90 of about 13,502,816 (309)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

ANALYTICAL REVIEW OF THE NORMATIVE BASE TO PROVIDE THE GOOD QUALITY OF PRECLINICAL STUDIES IN RUSSIA

Разработка и регистрация лекарственных средств, 2019
The main goal of preclinical studiesis the development of effective, high-quality and safe drugs. The task of preclinical studiesis to obtain exhaustive information, reliable and reproducible results.
A. I. Selezneva, S. V. Glembotsky, S. V. Polyakov, M. N. Makarova, V. G. Makarov, A. A. Churin   +5 more
doaj  

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Five preclinical studies reporting abscopal effect in murine model had different biological endpoints.

, 2017
Five preclinical studies reporting abscopal effect in murine model had different biological endpoints.
Silvia Strolin (3769477), Lidia Strigari (51527), Gianluca Bossi (333041), Raffaella Marconi (3769480)   +3 more
core   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

A Narrative Review of Preclinical In Vitro Studies Investigating microRNAs in Myocarditis

Current Issues in Molecular Biology
According to the World Health Organization’s statement, myocarditis is an inflammatory myocardium disease. Although an endometrial biopsy remains the diagnostic gold standard, it is an invasive procedure, and thus, cardiac magnetic resonance imaging has ...
Olga Grodzka, Grzegorz Procyk, Małgorzata Wrzosek   +2 more
doaj   +1 more source

A Review of Preclinical Studies to Understand Fear During Adolescence

, 2015
A Review of Preclinical Studies to Understand Fear During ...
Jee Hyun Kim (13075509), DE Ganella (14876710)   +1 more
core  

A summary of the major outcomes from preclinical and clinical studies on exercise training regimens for subjects with PH.

, 2022
A summary of the major outcomes from preclinical and clinical studies on exercise training regimens for subjects with PH.
Magdalena Jasińska-Stroschein (7851635)
core   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Ethical implications of preclinical studies

Регуляторные исследования и экспертиза лекарственных средств, 2018
Animal experiments are fundamental for the biomedical science. The development of new drugs is always associated with a large number of preclinical experiments in animals.
I. N. Tyurenkov, E. M. Lomkina, D. V. Kurkin, D. A. Bakulin, E. V. Volotova   +4 more
doaj